phrykt

Generate Biomedicines, Inc. (GENB): who owns it and who trades it

As of Nov 16, 2026, GENB insiders reported 2 open-market sales worth $201K and 6 purchases worth $25.3M in the last 12 months, with 92% of the sale value made under pre-set 10b5-1 plans. The largest seller was Frances Arnold (Director), with $201K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Generate Biomedicines

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GENB

86 funds and institutions reported GENB shares worth $1.7B at the end of Q2 2026, about 78% of the company. The largest holder is Flagship Pioneering, LLC with 48.9%.

Funds and institutions (13F) 78%Everyone else 22%

10 largest owners, by share of the company

Flagship Pioneering, LLC48.9%
FMR LLC (Fidelity)4.1%
Capital World Investors3.3%
Braidwell LP2.6%
T. Rowe Price Associates1.7%
Norges Bank1.6%
ARCH Venture Management, LLC1.5%
HarbourVest Partners LLC1.3%
BlackRock, Inc.1.3%
Baker Bros. Advisors LP1.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Flagship Pioneering, LLC62.67M48.89%$1.1BNo change
FMR LLC (Fidelity)5.22M4.07%$88.1M+24%
Capital World Investors4.22M3.29%$71.1M+5%
Braidwell LP3.28M2.56%$55.4M-9%
T. Rowe Price Associates2.16M1.68%$36.4M+2%
Norges Bank2.09M1.63%$35.3MNew
ARCH Venture Management, LLC1.94M1.52%$32.8MNo change
HarbourVest Partners LLC1.72M1.34%$29.1MNo change
BlackRock, Inc.1.66M1.29%$28MNew
Baker Bros. Advisors LP1.42M1.11%$24MNo change
JPMorgan Chase & Co1.41M1.10%$23.8MNew
Deep Track Capital, LP1.33M1.04%$22.5MNew
ARK Investment Management LLC1.28M1.00%$21.7M+158%
Vanguard Capital Management LLC1.13M0.88%$19.1M+763%
Harvard Management Co Inc1.11M0.87%$18.7MNo change
Nvidia Corp833,3250.65%$14.1MNo change
Davern Capital Partners, LP824,6790.64%$13.9M+39%
Siren, L.L.C.736,1040.57%$12.4MNo change
Geode Capital Management, LLC735,0030.57%$12.4M+522%
State Street Corp526,5650.41%$8.9MNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, GENB insiders reported $25.3M of open-market purchases and $201K of sales. 92% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$25.3M
6 trades, 5 people
Sales, 12 months
$201K
2 trades, 1 people
Sales under a 10b5-1 plan
92%
Share of sale value
Latest trade
Oct 29, 2026
Filed Nov 4, 2026

Purchases and sales by month

$25.3M$25.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 29, 2026Frances ArnoldDirectorSale plan11,409$16.19$185KForm 4
Sep 1, 2026Frances ArnoldDirectorSale1,000$16.00$16KForm 4
Mar 4, 2026Michael NallyCEOPurchase20,000$12.00$240KForm 4
Mar 2, 2026Beth GrousChief People OfficerPurchase300$16.00$4.8KForm 4
Mar 2, 2026Jason SilversCFOPurchase1,000$16.00$16KForm 4
Mar 2, 2026Jason SilversCFOPurchase500$16.00$8KForm 4
Mar 2, 2026Nutritional Health LTP Fund General Partner LLC +710% ownerPurchase1.56M$16.00$25MForm 4
Mar 2, 2026Jane L MendilloDirectorPurchase1,500$16.00$24KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Nutritional Health LTP Fund General Partner LLC10% owner$25M–Mar 2, 2026
Michael NallyChief Executive Officer, Director$240K–Mar 4, 2026
Frances ArnoldDirector–$201KOct 29, 2026
Jason SilversPresident & CFO$24K–Mar 2, 2026
Jane L MendilloDirector$24K–Mar 2, 2026
Beth GrousChief People Officer$4.8K–Mar 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GENB short interest

Moderate short interest. 7.0% of GENB shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 163%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.08M GENB shares were sold short, 7.0% of the shares outstanding, up 1.7% from the report before. At the average daily volume of 1.02M shares, buying them all back would take about 8.9 trading days (days to cover).

Shares short, % of all shares

7.04%May 15Oct 307.69%

Days to cover

8.9May 15Oct 3017.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.08M7.04%+2%1.02M8.9
Oct 15, 20268.93M6.96%+20%1.12M8.0
Sep 30, 20267.42M5.78%+3%1.29M5.8
Sep 15, 20267.18M5.59%-4%991,0647.2
Aug 31, 20267.46M5.81%+2%1.99M3.7
Aug 14, 20267.29M5.68%+0%482,70615.1
Jul 31, 20267.28M5.67%+4%477,22415.2
Jul 15, 20266.99M5.45%+18%744,7029.4
Jun 30, 20265.92M4.62%+30%1.47M4.0
Jun 15, 20264.55M3.55%+11%939,3844.8
May 29, 20264.09M3.19%+18%843,8804.8
May 15, 20263.45M2.69%+9%404,3648.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Generate Biomedicines company events

Generate Biomedicines filed 5 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 12, 2026.

  1. Nov 12, 2026ResultsReleased financial results. Filing
  2. Aug 26, 2026AnnouncementShared information with investors. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. May 7, 2026ResultsReleased financial results. Filing
  5. Mar 2, 2026RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Famous investors that hold GENB

4 of the 50 well-known investors we track reported holding GENB in their latest 13F filing. The largest position is Cathie Wood's, worth $29.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 20261.96M$29.5M0.2%+53%
Israel Englander · Millennium ManagementQ3 2026541,886$8.1M0.0%+2371%
Ken Griffin · Citadel AdvisorsQ3 202638,272$575K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202629,603$445K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named GENB in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G5.6%
Nov 5, 2026FMR LLC13G5.6%

Questions about Generate Biomedicines, Inc. (GENB) stock

Who owns the most GENB stock?

The largest reported owner of Generate Biomedicines, Inc. (GENB) is Flagship Pioneering, LLC, with 48.9% of the company. In total, 86 funds and institutions reported holding GENB at the end of Q2 2026, together about 78% of the shares. See the largest owners.

Are GENB insiders buying or selling?

In the last 12 months, GENB insiders reported 6 open-market purchases worth $25.3M and 2 sales worth $201K. The latest trade was on Oct 29, 2026. See every trade.

What is the short interest in GENB?

As of Oct 30, 2026, 9.08M GENB shares were sold short, 7.0% of the shares outstanding, up 1.7% from the report before. At the average daily volume of 1.02M shares, buying them all back would take about 8.9 trading days (days to cover). See the history.

Which famous investors hold GENB?

4 of the 50 well-known investors we track reported GENB in their latest 13F filing, including Cathie Wood, Israel Englander, Ken Griffin. The largest position is worth $29.5M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.